Diazepam (Libervant) vs Midazolam (Nayzilam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Libervant)
Developed by Eton Pharmaceuticals, Inc. under a licence from Aquestive Therapeutics, Inc.
NCT03428360 · Phase 3 · completed
The study treated 130 participants with diazepam buccal film in a single open-label group, without randomization, blinding, or a control arm. Its primary outcomes were safety event counts rather than a controlled clinical comparison, so the findings cannot establish comparative treatment effectiveness.
Reported efficacy
Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) (Adverse events (AEs) were recorded from Day 1 through the last study contact (Month 7 telephone contact).); Number of Subjects in Safety Analysis Set With Adverse Events of Special Interest (AESI) (AESIs were recorded from Day 1 through the last study contact (Month 7 telephone contact).): Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) (Adverse events (AEs) were recorded from Day 1 through the last study contact (Month 7 telephone contact).): Safety Analysis Set: Enrolled Subjects With Epilepsy Who Received at Least 1 Dose of Study Drug — At least 1 TEAE: 84 Participants; At least 1 severe TEAE: 14 Participants; At least 1 study drug related TEAE: 10 Participants; At least 1 severe and related TEAE: 1 Participants; At least 1 serious TEAE: 18 Participants; At least 1 serious and related TEAE: 1 Participants (not_applicable)
Result source: NCT03428360
Midazolam (Nayzilam)
Marketed by UCB
NCT01390220 · Phase 3 · terminated
This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).
Reported efficacy
Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 (met)
Result source: NCT01390220
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Diazepam (Libervant) | Midazolam (Nayzilam) |
|---|---|---|
| Seizure frequency, % change | —Not reported | —Not reported |
| 50% responder rate | —Not reported | —Not reported |
| Seizure freedom | —Not reported | 54.8% vs 38.7%+16.1 vs placeboNCT01999777 |
Seizure frequency, % change
- Diazepam (Libervant)
- —Not reported
- Midazolam (Nayzilam)
- —Not reported
50% responder rate
- Diazepam (Libervant)
- —Not reported
- Midazolam (Nayzilam)
- —Not reported
Seizure freedom
- Diazepam (Libervant)
- —Not reported
- Midazolam (Nayzilam)
- 54.8% vs 38.7%+16.1 vs placeboNCT01999777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Diazepam (Libervant): 2 of 4 rows · Midazolam (Nayzilam): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Diazepam (Libervant) | Midazolam (Nayzilam) |
|---|---|---|
| Dropout rate | —Diazepam Buccal Film Following a H NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2 show 1 more result—Diazepam Buccal Film Following a M NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2 | —5 mg + 5 mga NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 31.2%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Discontinued due to AEs | —Diazepam Buccal Film Following a H NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2 show 1 more result—Diazepam Buccal Film Following a M NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2 | —5 mg + 5 mga NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 5.8%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 — NCT01999777 · Phase 3 · monotherapy |
| Serious AEs | 0%Diazepam Buccal Film Following a H NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2 show 1 more result0%Diazepam Buccal Film Following a M NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2 | 0%5 mg + 5 mga NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results0%5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 0.7%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Most frequent reported AEs | sedation 10% dizziness 0% dysgeusia 0% NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2 show 1 more resultsomnolence 22.6% dysgeusia 6.5% fatigue 6.5% NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2 | 5 mg + 5 mga nasal discomfort 16.3% (placebo 7.3%) somnolence 9.3% (placebo 9.8%) throat irritation 7% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 show 3 more results5 mg only somnolence 9.9% (placebo 9.8%) headache 6.6% (placebo 0%) nasal discomfort 5.5% (placebo 7.3%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 7.3%) somnolence 9.6% (placebo 9.8%) lacrimation increased 6.8% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 16.1%) nausea 9.7% (placebo 3.2%) throat irritation 9.7% (placebo 9.7%) NCT01999777 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Midazolam (Nayzilam)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Libervant)'s landscape · Midazolam (Nayzilam)'s landscape